India's first COVID-19 vaccine, COVAXIN, by Bharat Biotech gets DCGI nod for human clinical trials
The Phase I and Phase II clinical trials of the vaccine for SARS-CoV-2, approved after pre-clinical studies demonstrated safety and immune response, would start across the country next month.
Hyderabad: The country's 'first' indigenous COVID-19 vaccine COVAXIN, developed by city-based Bharat Biotech in collaboration with ICMR and NIV, has got the nod for human clinical trials from the Drug Controller General of India, the company said on Monday.
The Phase I and Phase II clinical trials of the vaccine for SARS-CoV-2, approved after pre-clinical studies demonstrated safety and immune response, would start across the country next month.
The collaboration with Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV) was instrumental in the development of the vaccine, the company said in a release.
A new visualisation of the COVID-19 virus. Fusion Medical Animation/Unsplash
The indigenous and inactivated vaccine has been developed at Bharat Biotechs BSL-3 (Bio-Safety Level 3) high containment facility located in the Genome Valley, a release said.
The Drug Controller General of India CDSCO (The Central Drugs Standard Control Organisation), Ministry of Health & Family Welfare granted permission to initiate Phase I & II Human clinical trials after the company submitted results generated from pre-clinical studies, demonstrating safety and immune response. Human clinical trials are scheduled to start across India in July 2020, the release said.
Chairman and Managing Director of the company Dr. Krishna Ella said: We are proud to announce COVAXIN, Indias first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine.
"The proactive support and guidance from CDSCO has enabled approvals to this project. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform," he said.
Expedited through the national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies. Results from these studies have been promising and show extensive safety and effective immune responses, the released added.
Besides Bharat Biotech, at least five other Indian companies are working on a vaccine for the deadly coronavirus while similar efforts are underway in different countries.
.
also read
World happier than before Covid pandemic; West slightly lesser than others: Global Happiness Index
"People eventually learned who their neighbours were. They took care of the senior citizens, so the isolation was less severe than you might anticipate. Positive emotions have remained twice as common as negative ones even during these challenging years
WHO accuses China of hiding data on coronavirus origin
The WHO rebuked Chinese officials for withholding scientific research that may reveal the origin of the coronavirus and also asked them about the reasons behind not revealing the data three years ago and why, after it was published online in January, it could not be found now.
Delhi logs 153 fresh COVID-19 cases, positivity rate jumps to 9.13%
Delhi reported 139 cases with a positivity rate of 4.98 per cent on Saturday. It saw 152 cases with a positivity rate of 6.66 per cent on Friday and 117 cases with a positivity rate of 4.95 per cent on Thursday